MHLW Warns Of Of Higher Risk Of Aggressive Behavior In Patients On Antidepressants
This article was originally published in PharmAsia News
Executive Summary
Japan's Ministry of Health, Labor and Welfare June 24 called attention to SSRI and SNRI antidepressants. The ministry cited a higher risk of aggressive behaviors towards others and required physicians to use caution when prescriptions. The SSRI drugs currently available in Japan include Paxil (paroxetine), Luvox (fluvoxamine), Depromel (fluvoxamine) and Zoloft (sertraline). The most prescribed drug is Paxil with estimated annual prescriptions of 1.23 million. (Click here for more - Japanese language
You may also be interested in...
Pharma Can Pursue Claims Against Providers For 340B Duplicate Discounts In Medicaid Managed Care, HRSA Says
The statement, which is part of a final rule on the 340B administrative dispute resolution process, could facilitate manufacturer efforts to seek repayments from hospitals in such cases.
The Aspirin Test For AI?
US FDA Commissioner Robert Califf tells Congress that regulators don’t have to know how artificial intelligence works in medicine, but must make very sure it actually does work.
Mary Beth Clarke, CDER Exec Programs Office Director And Generic User Fee Shepherd, Will Retire
Clarke helped launch GDUFA I and negotiate GDUFA II, chaired the CDER Executive Committee and oversaw many other programs in the US FDA’s drugs center.